Study results of microbiotic therapeutics for Clostridioides difficile infection (CDI) and a microbial dietary score that points to increased cancer risk are the microbiome advances from Digestive Disease Week 2023, as selected by Dr Purna Kashyap, from the Mayo Clinic in Rochester, Minnesota.
Dr Kashyap starts with four studies examining microbiotic therapeutics for patients with CDI; the first two looked at RBX2660, which was recently approved by the US Food and Drug Administration (FDA).
The first study showed that clonal engraftment of RBX2660 microbiota was associated with clinical response to the treatment, while the second indicated that the therapy is safe and effective in immunocompromised patients.
Next, Dr Kashyap discusses a study of SER-109, also recently approved by the FDA. ESOSPOR IV revealed that the oral microbiome therapeutic achieved durable responses, even in patients with two or more CDI recurrences.
After discussing a final CDI study that may provide a mechanism for the effectiveness of the live biotherapeutic VE303, he moves on to colon cancer.
Dr Kashyap explains that a microbial dietary score was found to be associated not only with low-quality diets but also with an increased risk for colorectal cancer.
--
Purna C. Kashyap, MBBS, Professor of Medicine and Physiology; Consultant, Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
Purna C. Kashyap, MBBS, has disclosed no relevant financial relationships.
Digestive Disease Week® was sponsored by the American Gastroenterological Association, the American Association for the Study of Liver Diseases, the American Society for Gastrointestinal Endoscopy, and the Society for Surgery of the Alimentary Tract.
